Professional
Added to YB: 2025-02-14
Pitch date: 2025-01-26
LQDA [bullish]
Liquidia Corporation
+162.74%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.
Market Cap
$3.0B
Pitch Price
$14.33
Price Target
N/A
Dividend
N/A
EV/EBITDA
-61.70
P/E
-42.93
EV/Sales
18.94
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
Arquitos Capital Management Portfolio Holding: Liquidia Corporation
LQDA: FDA approval for Yutrepia expected May 2025. Superior to UTHR's Tyvaso in PAH/PH-ILD treatment. Clinical data shows 33 bps vs 9-12 bps, better outcomes. $1.7B market, 4x growth in 5 years. $1B market cap, multiples higher potential post-launch. Buyout possible within a year.
Read full article (4 min)